Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Barras

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Nursing & Health Sciences|February 3, 2016
Direct oral anticoagulants: New drugs with practical problems. How can nurses help prevent patient harm?Michael A Barras, David Hughes, Melanie Ullner
Internal Medicine Journal|May 16, 2017
Individualised medicine: why we need Bayesian dosingJoni Donagher, Jennifer H Martin, Michael A Barras
British Journal of Clinical Pharmacology|June 25, 2010
Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international surveyMichael A Barras, Carl M J Kirkpatrick, Bruce Green
Australian Prescriber|December 6, 2023
Digital health and prescribing: declare the past, diagnose the present, foretell the futureJodie A Austin, Michael A Barras, Clair M Sullivan
Therapeutic Drug Monitoring|January 15, 2016
Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot StudyKatharine R Dekker, Brooke L Myers, Michael A Barras
Therapeutic Drug Monitoring|July 2, 2010
Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrationsMichael A Barras, Stephen B Duffull, John J Atherton, et al.
Clinical Pharmacokinetics|December 12, 2013
Reporting a population pharmacokinetic-pharmacodynamic study: a journal's perspectiveKris M Jamsen, Sarah C McLeay, Michael A Barras, et al.
The Canadian Journal of Hospital Pharmacy|August 28, 2019
Developing Preliminary Steps in a Pharmacist Communication - Patient Outcome PathwayBernadette Chevalier, Bernadette M Watson, Michael A Barras, et al.
British Journal of Clinical Pharmacology|November 18, 2009
Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising eventsMichael A Barras, Stephen B Duffull, John J Atherton, et al.
Clinical Pharmacokinetics|August 10, 2010
Routine plasma anti-Xa monitoring is required for low-molecular-weight heparinsHesham S Al-Sallami, Michael A Barras, Bruce Green, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Nursing & Health Sciences|February 3, 2016
Direct oral anticoagulants: New drugs with practical problems. How can nurses help prevent patient harm?Michael A Barras, David Hughes, Melanie Ullner
Internal Medicine Journal|May 16, 2017
Individualised medicine: why we need Bayesian dosingJoni Donagher, Jennifer H Martin, Michael A Barras
British Journal of Clinical Pharmacology|June 25, 2010
Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international surveyMichael A Barras, Carl M J Kirkpatrick, Bruce Green
Australian Prescriber|December 6, 2023
Digital health and prescribing: declare the past, diagnose the present, foretell the futureJodie A Austin, Michael A Barras, Clair M Sullivan
Therapeutic Drug Monitoring|January 15, 2016
Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot StudyKatharine R Dekker, Brooke L Myers, Michael A Barras
Therapeutic Drug Monitoring|July 2, 2010
Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrationsMichael A Barras, Stephen B Duffull, John J Atherton, et al.
Clinical Pharmacokinetics|December 12, 2013
Reporting a population pharmacokinetic-pharmacodynamic study: a journal's perspectiveKris M Jamsen, Sarah C McLeay, Michael A Barras, et al.
The Canadian Journal of Hospital Pharmacy|August 28, 2019
Developing Preliminary Steps in a Pharmacist Communication - Patient Outcome PathwayBernadette Chevalier, Bernadette M Watson, Michael A Barras, et al.
British Journal of Clinical Pharmacology|November 18, 2009
Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising eventsMichael A Barras, Stephen B Duffull, John J Atherton, et al.
Clinical Pharmacokinetics|August 10, 2010
Routine plasma anti-Xa monitoring is required for low-molecular-weight heparinsHesham S Al-Sallami, Michael A Barras, Bruce Green, et al.
Pageof 3